multivalency to combat emerging and re‐emerging infectious diseases. Molecular Pharmaceutics 9: 342–354.63 Mishra, S., Webster, P., and Davis, M.E. (2004). PEGylation significantly affects cellular uptake and intracellular trafficking of non‐viral gene delivery particles. European Journal of Cell Biology 83: 97–111.
64 Owens, D.E. and Peppas, N.A. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics 307: 93–102.
65 Peters, R., Kramer, E., Oomen, A.G. et al. (2012). Presence of nano‐sized silica during in vitro digestion of foods containing silica as a food additive. ACS Nano 6: 2441–2451.
66 Podolsky, D.K. (2002). Inflammatory bowel disease. The New England Journal of Medicine 347: 417–429.
67 Powers, K.W., Palazuelos, M., Moudgil, B.M., and Roberts, S.M. (2007). Characterization of the size, shape, and state of dispersion of nanoparticles for toxicological studies. Nanotoxicology 1: 42–51.
68 Riasat, R., Guangjun, N., Riasat, N. et al. (2016). Effects of nanoparticles on gastrointestinal disorders and therapy. Journal of Clinical Toxicology 6 (313): 1–10.
69 Romberg, B., Hennink, W.E., and Storm, G. (2008). Sheddable coatings for long‐circulating nanoparticles. Pharmaceutical Research 25: 55–71.
70 Seabra, C.L., Nunes, C., and Gomez‐Lazaro, M. (2017). Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori. International Journal of Pharmaceutics 519: 128–137.
71 Senanayake, T.H., Warren, G., Wei, X., and Vinogradov, S.V. (2013). Application of activated nucleoside analogs for the treatment of drug‐resistant tumors by oral delivery of nanogel‐drug conjugates. Journal of Controlled Release 167: 200–209.
72 Seydack, M. (2004). Nanoparticle labels in immunosensing using optical detection methods. Biosensors and Bioelectronics 20: 2454–2469.
73 Stang, J., Haynes, M., Carson, P., and Moghaddam, M. (2012). A preclinical system prototype for focused microwave thermal therapy of the breast. IEEE Transactions on Biomedical Engineering 59: 2431–2438.
74 Szentkuti, L. (1997). Light microscopical observations on luminally administered dyes, dextrans, nanospheres and microspheres in the pre‐epithelial mucus gel layer of the rat distal colon. Journal of Controlled Release 46: 233–242.
75 Thamphiwatana, S., Fu, V., Zhu, J. et al. (2013). Nanoparticle‐stabilized liposomes for pH‐responsive gastric drug delivery. Langmuir 29: 12228–12233.
76 Tiernan, J.P., Ingram, N., Marston, G. et al. (2015). CEA‐targeted nanoparticles allow specific in vivo fluorescent imaging of colorectal cancer models. Nanomedicine (London, England) 10: 1223–1231.
77 Tokajuk, G., Niemirowicz, K., Deptuła, P. et al. (2017). Use of magnetic nanoparticles as a drug delivery system to improve chlorhexidine antimicrobial activity. International Journal of Nanomedicine 12: 7833–7846.
78 Torchilin, V.P. (2007). Targeted pharmaceutical nanocarriers for cancer therapy and imaging. The AAPS Journal 9: E128–E147.
79 Umamaheshwari, R.B. and Jain, N.K. (2003). Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. Journal of Drug Targeting 11: 415–424.
80 Vigor, K.L., Kyrtatos, P.G., Minogue, S. et al. (2010). Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. Biomaterials 31: 1307–1315.
81 Viswanath, B., Kim, S., and Lee, K. (2016). Recent insights into nanotechnology development for detection and treatment of colorectal cancer. International Journal of Nanomedicine 11: 2491–2504.
82 Walczak, A.P., Fokkink, R., Peters, R. et al. (2013). Behaviour of silver nanoparticles and silver ions in an in vitro human gastrointestinal digestion model. Nanotoxicology 7: 1198–1210.
83 Walczak, A.P., Kramer, E., Hendriksen, P.J. et al. (2015). In vitro gastrointestinal digestion increases the translocation of polystyrene nanoparticles in an in vitro intestinal co‐culture model. Nanotoxicology 9: 886–894.
84 Weinberg, W.C., Frazier‐Jessen, M.R., Wu, W.J. et al. (2005). Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Reviews 24: 569–584.
85 Weissleder, R., Kelly, K., Sun, E.Y. et al. (2005). Cell‐specific targeting of nanoparticles by multivalent attachment of small molecules. Nature Biotechnology 23: 1418–1423.
86 Westmeier, D., Posselt, G., Hahlbrock, A. et al. (2018). Nanoparticle binding attenuates the pathobiology of gastric cancer‐associated Helicobacter pylori. Nanoscale 10: 1453–1463.
87 Xiao, B. and Merlin, D. (2012). Oral colon‐specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opinion in Drug Delivery 9: 1393–1407.
88 Zhu, X. and Gao, T. (2019). Spectrometry. In: Nano‐Inspired Biosensors for Protein Assay with Clinical Applications (ed. G. Li), 237–264. Amsterdam, Netherlands: Elsevier.
89 Zottel, A., Videtič, A., and Jovcevska, A. (2019). Nanotechnology meets oncology: nanomaterials in brain cancer research, diagnosis and therapy. Materials 12: 1–28.
Конец ознакомительного фрагмента.
Текст предоставлен ООО «ЛитРес».
Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.
Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.
